Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

PURPOSE: Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Maurer, Matthew J., Ghesquières, Hervé, Link, Brian K., Jais, Jean-Philippe, Habermann, Thomas M., Thompson, Carrie A., Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B., Delarue, Richard, Micallef, Ivana N., Peyrade, Frederic, Inwards, David J., Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R., Molina, Thierry J., Syrbu, Sergei, Feldman, Andrew L., Slager, Susan L., Weiner, George J., Ansell, Stephen M., Cerhan, James R., Salles, Gilles A., Witzig, Thomas E., Tilly, Hervé, Nowakowski, Grzegorz S.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2018
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978469/
https://ncbi.nlm.nih.gov/pubmed/29672223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.5198
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料